Dynavax Technologies Authorizes $200 Million Stock Repurchase

MT Newswires Live11-08

Dynavax Technologies (DVAX) said late Thursday that it has authorized the repurchase of up to $200 million in stock.

The repurchase program lacks an expiration date. The pharmaceutical company said it expects that purchases to be completed within a year.

Price: 11.61, Change: -0.17, Percent Change: -1.44

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment